GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SCYNEXIS Inc (LTS:0L49) » Definitions » Cyclically Adjusted PB Ratio

SCYNEXIS (LTS:0L49) Cyclically Adjusted PB Ratio : 0.17 (As of May. 27, 2024)


View and export this data going back to 2018. Start your Free Trial

What is SCYNEXIS Cyclically Adjusted PB Ratio?

As of today (2024-05-27), SCYNEXIS's current share price is $2.33. SCYNEXIS's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $14.04. SCYNEXIS's Cyclically Adjusted PB Ratio for today is 0.17.

The historical rank and industry rank for SCYNEXIS's Cyclically Adjusted PB Ratio or its related term are showing as below:

LTS:0L49' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.1   Med: 0.32   Max: 0.68
Current: 0.17

During the past years, SCYNEXIS's highest Cyclically Adjusted PB Ratio was 0.68. The lowest was 0.10. And the median was 0.32.

LTS:0L49's Cyclically Adjusted PB Ratio is ranked better than
92.94% of 694 companies
in the Drug Manufacturers industry
Industry Median: 1.855 vs LTS:0L49: 0.17

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

SCYNEXIS's adjusted book value per share data for the three months ended in Mar. 2024 was $1.961. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $14.04 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


SCYNEXIS Cyclically Adjusted PB Ratio Historical Data

The historical data trend for SCYNEXIS's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SCYNEXIS Cyclically Adjusted PB Ratio Chart

SCYNEXIS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 0.29 0.23

SCYNEXIS Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.56 0.55 0.43 0.23 0.10

Competitive Comparison of SCYNEXIS's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, SCYNEXIS's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SCYNEXIS's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SCYNEXIS's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where SCYNEXIS's Cyclically Adjusted PB Ratio falls into.



SCYNEXIS Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

SCYNEXIS's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=2.33/14.04
=0.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SCYNEXIS's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, SCYNEXIS's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.961/131.7762*131.7762
=1.961

Current CPI (Mar. 2024) = 131.7762.

SCYNEXIS Quarterly Data

Book Value per Share CPI Adj_Book
201406 46.369 100.560 60.763
201409 42.460 100.428 55.714
201412 39.275 99.070 52.241
201503 32.177 99.621 42.563
201506 40.832 100.684 53.441
201509 35.935 100.392 47.169
201512 30.167 99.792 39.836
201603 25.199 100.470 33.051
201606 18.730 101.688 24.272
201609 14.159 101.861 18.317
201612 14.149 101.863 18.304
201703 13.131 102.862 16.822
201706 11.956 103.349 15.245
201709 9.622 104.136 12.176
201712 7.390 104.011 9.363
201803 7.865 105.290 9.844
201806 5.668 106.317 7.025
201809 5.907 106.507 7.308
201812 6.509 105.998 8.092
201903 2.256 107.251 2.772
201906 1.908 108.070 2.327
201909 1.071 108.329 1.303
201912 1.324 108.420 1.609
202003 0.660 108.902 0.799
202006 0.604 108.767 0.732
202009 0.885 109.815 1.062
202012 1.157 109.897 1.387
202103 1.257 111.754 1.482
202106 1.396 114.631 1.605
202109 1.575 115.734 1.793
202112 1.437 117.630 1.610
202203 1.332 121.301 1.447
202206 1.395 125.017 1.470
202209 0.527 125.227 0.555
202212 0.099 125.222 0.104
202303 -0.898 127.348 -0.929
202306 2.504 128.729 2.563
202309 2.474 129.860 2.511
202312 1.961 129.419 1.997
202403 1.961 131.776 1.961

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


SCYNEXIS  (LTS:0L49) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


SCYNEXIS Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of SCYNEXIS's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


SCYNEXIS (LTS:0L49) Business Description

Traded in Other Exchanges
Address
1 Evertrust Plaza, 13th Floor, Jersey City, NJ, USA, 07302 - 6548
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains.

SCYNEXIS (LTS:0L49) Headlines

No Headlines